TaiMed Biologics has obtained approval from the US Food and Drug Administration (FDA) for HIV drug Trogarzo (ibalizumab-uiyk) for heavily treatment-experienced patients.

The antiretroviral medication is indicated for patients who have not responded to  existing drugs due to multidrug resistant HIV (MDR HIV) infection.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is administered intravenously once every 14 days by a trained medical professional and used in combination with other antiretroviral medications.

“Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options.”

Deputy director of the antiviral products division of the FDA’s Center for Drug Evaluation and Research Jeff Murray said: “While most patients living with HIV can be successfully treated using a combination of two or more antiretroviral drugs, a small percentage of patients who have taken many HIV drugs in the past have multidrug resistant HIV, limiting their treatment options and putting them at a high risk of HIV-related complications and progression to death.

“Trogarzo is the first drug in a new class of antiretroviral medications that can provide significant benefit to patients who have run out of HIV treatment options.”

TaiMed Biologics assessed the safety and efficacy of Trogarzo in a clinical trial involving 40 heavily treatment-experienced MDR HIV-1 patients who had high HIV-RNA levels in their blood even after using antiretroviral drugs.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A week after Trogarzo was added to their antiretroviral regimens, the majority of the subjects demonstrated a significant reduction in virus levels, and 43% experienced HIV-RNA suppression after 24 weeks.